Therapeutic strategies for castration-resistant prostate cancer are limited, and the emergence of neuroendocrine differentiation in CRPC patients as a result of treatment with second generation of AR pathway inhibitors poses significant clinical challenges. This evidence concerns the gene AR and prostate carcinoma.